Related Experiment Videos
Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits
Abstract:
To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg or daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed animal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.
Insights
ICRF-187 can reduce chronic daunorubicin cardiac toxicity in rabbits. This finding suggests ICRF-187 may protect against heart damage from daunorubicin chemotherapy.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Daunorubicin is an effective chemotherapy agent but can cause significant cardiac toxicity.
- Chronic daunorubicin administration leads to cellular damage in the heart, including vacuolization and myofibrillar loss.
Purpose of the Study:
- To evaluate the protective effect of ICRF-187 against daunorubicin-induced cardiotoxicity.
- To determine if ICRF-187 can mitigate the cellular alterations associated with chronic daunorubicin treatment.
Main Methods:
- Male New Zealand rabbits received daunorubicin intravenously (IV) alone or pretreated with ICRF-187 intraperitoneally (IP).
- Dosing occurred at 3-week intervals for five injections, with cardiac toxicity assessed three weeks after the final dose.
- Histopathological analysis graded cellular alterations on a scale of 0 to 4.
Main Results:
- All rabbits receiving daunorubicin alone showed cardiac lesions (average severity 1.8).
- Rabbits pretreated with ICRF-187 exhibited significantly reduced cardiac abnormalities (average severity 0.9).
- No abnormalities were observed in a portion of ICRF-187 treated rabbits.
Conclusions:
- Concurrent administration of ICRF-187 may reduce chronic daunorubicin-induced cardiac toxicity.
- ICRF-187 shows potential as a cardioprotective agent when used with daunorubicin chemotherapy.